Goldman Sachs analyst Richard Law initiated coverage of Protagonist Therapeutics (PTGX) with a Neutral rating and $47 price target Both of the company’s Phase 3 assets can succeed commercially, but they have already been licensed and offer “limited” financial and M&A upside, the analyst tells investors in a research note. Given that Protagonist’s stock price has risen over 400% in the past two years from development progression and licensing deals, the company’s current price already reflects upside from both assets, the firm added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics initiated with an Outperform at BMO Capital
- Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
- Protagonist Therapeutics price target raised to $67 from $51 at BTIG
- Protagonist Therapeutics selects PN-881 as development candidate
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint